| Metric / Dimension | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 76 | Hyper-growth biotech in expansion phase; positive momentum offset by profitability gaps and elevated beta. YoY revenue growth 39.6% affirms secular healthcare demand; negative EPS (-$3.40) reflects R&D intensity typical of pre-profit innovation stage. | 6–12M |
| SA Quality/Value Composite | C+ | 58 | P/E unavailable (negative earnings); EV/Revenue ratio (~51x on ~$397M implied TTM revenue) indicates premium valuation. No dividend yield. Revenue growth (39.6% YoY) supports quality narrative, but profitability not yet demonstrated. Fair value assessment constrained by earnings visibility gap. | 6–12M |
| Zacks Earnings Momentum | D | 42 | EPS -$3.40 (negative); EPS growth YoY not disclosed. Lack of earnings inflection visibility. No upcoming earnings date flagged in dataset. Momentum contingent on clinical/commercialization catalysts, not financial runway. | 1–3M |
| Institutional & Smart Money Flow | B | 72 | +5.75% daily move (Aug 1 session); 52-week return +232.6% (massive institutional repricing). $20.2B market cap signals established institutional presence. Weekly avg volume 1.86M shares indicates strong liquidity. Growth flag "hyper_growth" confirms institutional thesis alignment. | 1–3M |
| Growth Sustainability & Moat | B | 74 | Guardant Health (liquid biopsy/cancer diagnostics) operates in secular high-growth oncology market. Revenue growth 39.6% YoY supports moat strength in precision medicine. Beta 1.63 indicates market leadership with above-average systematic sensitivity. No weakness flags on balance sheet. Sector (Health Care) commands defensive premium. | 6–12M |
| Valuation & Safety (Pre-Penalty) | C | 54 | Current price $152.35; 52-week range $40.35–$174.08 (wide swing suggests volatility). Enterprise value $20.17B on ~$397M implied revenue (51x EV/Rev) is elevated but justified by growth rate and moat. Forward P/E not available (earnings inflection pending). Safety margin modest given beta 1.63 and negative earnings. | 6–12M |
| Penalty Overlay | C | −12 | Profitability penalty: strong_profitability = false (−5 pts). Earnings visibility gap (no forward guidance disclosed): −4 pts. High valuation (relative to current earnings): −3 pts. Mitigated slightly by hyper-growth flag (+2 pts offset). | 6–12M |
| CONFIDENCE SCORE | B | 69 | High confidence in revenue trajectory and sector tailwinds. Moderate confidence in profitability timeline (limited earnings disclosure). Strong liquidity and institutional adoption reduce execution risk. Data gaps (earnings date, forward guidance) prevent higher confidence tier. | 6–12M |
| Volatility & Drawdown Risk | D+ | 48 | Beta 1.63 (63% more volatile than broad market). 52-week drawdown from $174.08 to current $152.35 (−12.5% from recent high) and prior low of $40.35 (−76.8% trough) illustrates high swing risk. No hedging instruments disclosed. Suitable for risk-tolerant institutional allocators only. | 3–6M |
| Crowding Risk Flag | C+ | 62 | 52-week return +232.6% and institutional inflows evident (beta, market cap growth). Liquid biopsy narrative widely covered. Valuation premium (51x EV/Rev) suggests partial consensus pricing. Crowding moderate; growth thesis well-known but execution risk remains high. | 6–12M |
Guardant Health (GH) competes in the high-growth precision oncology diagnostics segment, peer to Guardant, Foundation Medicine (acquired by Roche), Invitae, and established players (Illumina, Exact Sciences). GH's 39.6% revenue growth substantially outpaces mature diagnostics peers (~8–12% CAGR) and aligns with liquid biopsy adoption tailwinds. The firm's $20.2B valuation reflects institutional recognition of the secular cancer screening and early detection megatrend. However, elevated EV/Revenue multiple (51x) prices in high execution risk and near-term profitability inflection. Peer comparison constrained by earnings visibility gaps across the cohort.
Bullish near-term momentum: +5.75% daily move, 52-week return +232.6%, institutional inflow signals (beta 1.63, $20B+ market cap). Catalyst-driven: likely clinical readouts, commercialization milestones, or M&A news. Risk: beta 1.63 exposes to sector-wide corrections and macro rate volatility. Earnings momentum score (D, 42 pts) reflects lack of near-term profit inflection visibility—focus remains on top-line execution and cash burn trajectory. Price near recent highs ($152.35 vs. $174.08 52-week peak) suggests limited upside without fresh catalysts.
Growth sustainability (B, 74 pts) and moat strength (oncology diagnostics, 39.6% YoY revenue growth) support favorable 6–12M positioning, contingent on profitability inflection and guidance upgrade. Valuation & Safety (C, 54 pts) remains the limiting factor: premium 51x EV/Revenue ratio leaves limited margin for error if growth disappoints or macro headwinds compress multiples. Medium-term upside hinges on: (1) successful transition to operating profitability, (2) sustained >30% revenue growth, (3) market share gains in liquid biopsy adoption. Downside risk (−12% from recent highs, −76.8% trough in 52-week range) illustrates execution sensitivity. Suitable for long-duration growth portfolios with high risk tolerance; unsuitable for income or capital preservation mandates.
Guardant Health (GH) merits a B+ (76/100) institutional research score, reflecting robust revenue growth (39.6% YoY), market leadership in precision oncology, and strong institutional adoption (beta 1.63, $20B+ cap). However, negative EPS (−$3.40), lack of profitability visibility, and elevated valuation (51x EV/Revenue) create meaningful execution risk. Suitable for growth-oriented allocators with 6–12 month horizon and high volatility tolerance; near-term catalysts favor tactical longs, but valuation premium demands disciplined position sizing and stop-loss discipline given beta 1.63 volatility and crowding signals.
As of 2026-07-31 | Price $152.35 | Confidence 69/100
GH Stock Analysis & Forecast
Is GH a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
GH Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, GH shows balanced risk-reward characteristics.
Should You Buy GH Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in GH.